Pexerelgon vs R2R01

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Heart Failure

Shared mechanism: Relaxin receptor (RXFP1) / relaxin · full Heart Failure pipeline

Pexerelgon

Developed by AstraZeneca

Phase 2 in Heart Failuresmall molecule
Partial signal

NCT06299826 · Phase 2 · completed

The study was randomized, double-blind, and placebo-controlled, with 375 participants across three AZD5462 dose groups and a placebo group. Its primary endpoint was a surrogate echocardiographic measure, and no primary-outcome results or statistical comparison are currently available.

No aligned efficacy figure on record for this race.

R2R01

Developed by River 2 Renal

Phase 2 in Heart Failurepeptide
Weak signal

NCT06264310 · Phase 2 · completed

The study randomly assigned participants to R2R01 or placebo and used blinded treatment, but only 33 participants were enrolled across four groups. Its primary endpoint was safety and tolerability, and no primary-endpoint results or statistical comparison are posted, so the trial provides limited evidence at this time. Its registered primary outcome on ClinicalTrials.gov is "Number and rate of patients with one or more TEAEs (treatment emergent AE's) and/or serious TEAEs as assessed by CTCAE v5.0." (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Results for Heart Failure

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPexerelgonR2R01
CV death or HF hospitalisation—Not reported—Not reported
HF hospitalisation—Not reported—Not reported
CV death—Not reported—Not reported
KCCQ clinical summary, change—Not reported—Not reported

CV death or HF hospitalisation

Pexerelgon
—Not reported
R2R01
—Not reported

HF hospitalisation

Pexerelgon
—Not reported
R2R01
—Not reported

CV death

Pexerelgon
—Not reported
R2R01
—Not reported

KCCQ clinical summary, change

Pexerelgon
—Not reported
R2R01
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Pexerelgon: no structured comparison results are available for Heart Failure.

R2R01: no structured comparison results are available for Heart Failure.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pexerelgon's landscape · R2R01's landscape